AU2013261214A1 - Polypeptide loaded POCA nanoparticles for oral administration - Google Patents

Polypeptide loaded POCA nanoparticles for oral administration Download PDF

Info

Publication number
AU2013261214A1
AU2013261214A1 AU2013261214A AU2013261214A AU2013261214A1 AU 2013261214 A1 AU2013261214 A1 AU 2013261214A1 AU 2013261214 A AU2013261214 A AU 2013261214A AU 2013261214 A AU2013261214 A AU 2013261214A AU 2013261214 A1 AU2013261214 A1 AU 2013261214A1
Authority
AU
Australia
Prior art keywords
nanoparticles
peptide
nanoparticle
exendin
metabolic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2013261214A
Other languages
English (en)
Inventor
Sean Matthew Cleveland
Mark Andrew Paulik
Stefan Salomon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of AU2013261214A1 publication Critical patent/AU2013261214A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5138—Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2013261214A 2012-05-16 2013-05-16 Polypeptide loaded POCA nanoparticles for oral administration Abandoned AU2013261214A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261647633P 2012-05-16 2012-05-16
US61/647,633 2012-05-16
PCT/IB2013/000964 WO2013171570A1 (en) 2012-05-16 2013-05-16 Polypeptide loaded poca nanoparticles for oral administration

Publications (1)

Publication Number Publication Date
AU2013261214A1 true AU2013261214A1 (en) 2014-11-20

Family

ID=48577784

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013261214A Abandoned AU2013261214A1 (en) 2012-05-16 2013-05-16 Polypeptide loaded POCA nanoparticles for oral administration

Country Status (10)

Country Link
US (1) US20150342897A1 (https=)
EP (1) EP2849775A1 (https=)
JP (1) JP2015523332A (https=)
KR (1) KR20150010953A (https=)
CN (1) CN104411321A (https=)
AU (1) AU2013261214A1 (https=)
CA (1) CA2873536A1 (https=)
IN (1) IN2014DN09297A (https=)
RU (1) RU2014150850A (https=)
WO (1) WO2013171570A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104799440B (zh) * 2014-01-23 2016-06-08 香港纺织及成衣研发中心有限公司 改善代谢综合症的功能服及其制造方法
CN105342999A (zh) * 2014-08-18 2016-02-24 山东绿叶制药有限公司 艾塞那肽口服纳米粒
CN109675020B (zh) * 2019-01-11 2021-05-04 浙江大学 一种口服glp-1多肽类纳米制剂及其制备方法和应用
MX2023006163A (es) 2020-12-18 2023-06-08 Spectrum Brands Inc Herramienta de cepillado para animales y metodos.

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE164852T1 (de) 1990-01-24 1998-04-15 Douglas I Buckley Glp-1-analoga verwendbar in der diabetesbehandlung
IE80468B1 (en) * 1995-04-04 1998-07-29 Elan Corp Plc Controlled release biodegradable nanoparticles containing insulin
ATE493998T1 (de) 1996-08-08 2011-01-15 Amylin Pharmaceuticals Inc Pharmazeutische zusammensetzung mit einem exendin-4-peptid
ES2293688T5 (es) 1997-08-08 2011-05-04 Amylin Pharmaceuticals, Inc. Nuevos compuestos análogos de la exendina.
ATE383867T1 (de) 1997-11-14 2008-02-15 Amylin Pharmaceuticals Inc Neuartige exendin agonisten
MXPA00004670A (es) 1997-11-14 2003-07-14 Amylin Pharmaceuticals Inc Compuestos agonistas de exendina novedosos.
EP1054594B1 (en) 1998-02-13 2007-07-04 Amylin Pharmaceuticals, Inc. Inotropic and diuretic effects of exendin and glp-1
JP2003522099A (ja) 1998-02-27 2003-07-22 ノボ ノルディスク アクティーゼルスカブ 遅延作用プロファイルを有するｇｌｐ−１のｇｌｐ−１誘導体及びエキセンジン
IL155812A0 (en) 2000-12-07 2003-12-23 Lilly Co Eli Glp-1 fusion proteins
AU2002364586A1 (en) 2001-12-21 2003-07-30 Delta Biotechnology Limited Albumin fusion proteins
WO2005003296A2 (en) 2003-01-22 2005-01-13 Human Genome Sciences, Inc. Albumin fusion proteins
WO2003059934A2 (en) 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Albumin fusion proteins
BR122019021416A2 (https=) 2003-09-19 2019-12-21
US7456254B2 (en) * 2004-04-15 2008-11-25 Alkermes, Inc. Polymer-based sustained release device
CN102016814B (zh) 2005-06-17 2013-10-23 北卡罗来纳大学查珀尔希尔分校 纳米粒子制备方法、系统及材料
US20080138418A1 (en) * 2006-12-07 2008-06-12 Tong Shen Enterprise Co., Ltd. Nanoparticles composed of alkyl-cyanoacrylate polymers
EP2207670B1 (en) 2007-10-12 2019-05-22 Liquidia Technologies, Inc. Method for producing particles and patterned films

Also Published As

Publication number Publication date
KR20150010953A (ko) 2015-01-29
WO2013171570A1 (en) 2013-11-21
CA2873536A1 (en) 2013-11-21
US20150342897A1 (en) 2015-12-03
RU2014150850A (ru) 2016-07-10
JP2015523332A (ja) 2015-08-13
EP2849775A1 (en) 2015-03-25
IN2014DN09297A (https=) 2015-07-10
CN104411321A (zh) 2015-03-11

Similar Documents

Publication Publication Date Title
Gedawy et al. Oral insulin delivery: existing barriers and current counter-strategies
Wong et al. The role of chitosan on oral delivery of peptide-loaded nanoparticle formulation
Chalasani et al. A novel vitamin B12-nanosphere conjugate carrier system for peroral delivery of insulin
Makhlof et al. Design and evaluation of novel pH-sensitive chitosan nanoparticles for oral insulin delivery
Chen et al. Long-acting release formulation of exendin-4 based on biomimetic mineralization for type 2 diabetes therapy
Hinds et al. PEGylated insulin in PLGA microparticles. In vivo and in vitro analysis
Wong Design of oral insulin delivery systems
Damgé et al. Poly (ε-caprolactone)/eudragit nanoparticles for oral delivery of aspart-insulin in the treatment of diabetes
Ahn et al. Oral delivery of an anti-diabetic peptide drug via conjugation and complexation with low molecular weight chitosan
Soudry-Kochavi et al. Improved oral absorption of exenatide using an original nanoencapsulation and microencapsulation approach
Ren et al. Utilization of PLGA nanoparticles in yeast cell wall particle system for oral targeted delivery of exenatide to improve its hypoglycemic efficacy
Seo et al. Sustained release of exendin 4 using injectable and ionic-nano-complex forming polymer hydrogel system for long-term treatment of type 2 diabetes mellitus
Alfatama et al. A comprehensive review of oral chitosan drug delivery systems: Applications for oral insulin delivery
Kumeria et al. Enteric polymer-coated porous silicon nanoparticles for site-specific oral delivery of IgA antibody
US20150342897A1 (en) Polypeptide loaded poca nanoparticles for oral administration
Presas et al. Pre-clinical evaluation of a modified cyclodextrin-based nanoparticle for intestinal delivery of liraglutide
US20100143484A1 (en) Oral submicron particle delivery system for proteins and process for its production
CN115190795A (zh) 聚乙二醇化尿酸酶的制剂和剂量
Li et al. Distribution, transition, adhesion and release of insulin loaded nanoparticles in the gut of rats
CN102657871B (zh) 一种口服缓释制剂、包载材料及制备方法
Lu et al. Net-neutral nanoparticles-extruded microcapsules for oral delivery of insulin
Chauhan et al. Therapeutic advancements in the management of diabetes mellitus with special reference to nanotechnology
Lee Glucagon‐Like Peptide‐1 Formulation–the Present and Future Development in Diabetes Treatment
Cheng et al. Design, preparation, and characterization of injectable thermosensitive polymer-based hydrogels with enhanced mechanical properties for sustained liraglutide release
Son et al. Mono-lithocholated exendin-4-loaded glycol chitosan nanoparticles with prolonged antidiabetic effects

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period